Table 1.
Characteristics of the included studies.
| Author, year | Country/Region | Income Level | Study Design/Article type | Vaccine of Interest | Type of Switch | Year of Switch |
|---|---|---|---|---|---|---|
| Bahl, 201725 | South-East Asia Region | Middle to High | Narrative review | Polio | Switch of serotype coverage (tOPV to bOPV) | 2016 |
| Califano, 201626 | Argentina | High | Narrative review | Polio | Switch of serotype coverage (tOPV to bOPV) | 2016 |
| Fahmy, 201727 | Eastern Mediterranean Region | Low to High | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
2016 |
| Freed, 200652 | US | High | Survey study | Combination vaccine (diphtheria, tetanus, acellular pertussis, hepatitis B, IPV) | Switch from multiple vaccinations to a combination vaccine (Pentavalent vaccine) | 2002 |
| Gamage, 201828 | Sri Lanka | Lower Middle | Narrative review | Polio | Switch of route of administration (OPV to IPV and IM to ID) | 2016 |
| Garg, 201829 | Southeast Asia Region | Middle to High | Narrative review | Polio | Switch of serotype coverage (tOPV to bOPV) | 2016 |
| Garon, 201730 | Global | NA | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
2016 |
| Garon, 201631 | Global | NA | Narrative review | Polio | Switch of serotype coverage (tOPV to bOPV) | 2016 |
| Gurung, 201732 | Western Pacific Region | Middle to High | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
2016 |
| Hampton, 201633 | Global | NA | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
2016 |
| Hampton, 201734 | Global | NA | Narrative review | Polio | Switch of serotype coverage (tOPV to bOPV) | NA |
| Horn, 202135 | Global | NA | Narrative review | PCV | Switch of serotype coverage (PCV7 to PCV10 or PCV13, PCV10 to PCV13, and PCV13 to PCV10) | 2009 |
| Icardi, 201836 | Global (Nigeria, Pakistan and Afghanistan were mentioned as examples) | NA | Narrative review | Polio | Switch of serotype coverage (tOPV to bOPV) | 2016 |
| Jog, 201637 | India | Lower Middle | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
2016 |
| John, 201338 | India | Lower Middle | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
NA |
| Kaucley, 202047 | Benin | Lower Middle | Survey study | PCV | Switch of number of doses per vial (single-dose vial to multi-dose vial) | 2011 |
| Kolasa, 20048 | US | High | Observational study | Polio DTP |
Switch of route of administration (OPV to IPV) and additional injection of DTaP) |
1997 |
| Menning, 201739 | Global | NA | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
2016 |
| Nafi, 201940 | Global | NA | Narrative review | Polio | Switch of route of administration (OPV to IPV) | NA |
| Orenstein, 201541 | Global | NA | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
NA |
| Pedreira, 201742 | Region of Americas | Middle to High | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
2015–2016 |
| Pervaiz, 201743 | Pakistan | Lower Middle | Narrative review | Polio | Switch of route of administration (OPV to IPV and IM to ID) | 2016 |
| Ramirez Gonzalez, 201744 | Global | NA | Narrative review | Polio PCV as an example |
Switch of serotype coverage (tOPV to bOPV) | 2016 |
| Snelling, 201545 | Global | NA | Narrative review | Pertussis | Switch of types of vaccines (whole cell to acellular) | NA |
| Soeters, 201949 | Burkina Faso | Low | Observational study | PCV | Switch of vaccination schedule (3 + 0 to 2 + 1) | NA |
| Suarez, 201650 | Peru | Upper Middle | Observational study | PCV | Switch of vaccination schedule (3, 5, and 12 months to 2, 4, and 12 months) Switch of serotype coverage (PCV7 to PCV10) |
2010 and 2011 |
| Tevi-Benissan, 201746 | African Region | Low to High | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
2016 |
| Thacker, 20163 | Global (Mainly Discussed on Pakistan, Afghanistan, India, and Nigeria) | Low to Lower Middle | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
2016 |
| Usuf, 201453 | Gambia | Low | Survey study | Combination vaccine and PCV | Switch from multiple vaccinations to a combination vaccine (Pentavalent vaccine) and introduction of PCV13 | 2009 |
| Wahjuhono, 201451 | Indonesia | Lower Middle | Prospective cohort study | Polio | Switch of route of administration (OPV to IPV) | 2007 |
| World Health Organization, Regional Office the Europe, 201654 | European Region | Low to High | News | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
2016 |
| Pan American Health Organization, 201755 | Region of Americas | Middle to High | Narrative review | Polio | Switch of route of administration (OPV to IPV) Switch of serotype coverage (tOPV to bOPV) |
2016 |
| Fine, 199956 | Not specified | NA | Narrative review | BCG | Switch of strains (switch to a more reactogenic strain vaccines) | NA |
Abbreviations: 2 + 1, 2 primary doses with a booster dose; 3 + 0, 3 primary doses without a booster dose; BCG, Bacillus Calmette-Guérin; bOPV, Bivalent Oral Poliovirus vaccine; DTaP, Diphtheria-Tetanus-Pertussis; ID, Intradermal; IM, Intramuscular; IPV, Inactivated Poliovirus vaccine; NA, Not Available; OPV, Oral Poliovirus vaccine; PCV, Pneumococcal Conjugate vaccine; tOPV, Trivalent Oral Poliovirus vaccine.